Trevi Therapeutics Inc (TRVI) Stock Price, Quote & News

Company Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phas...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 304 2499

Website: www.trevitherapeutics.com

Address:

195 Church Street, 16th Floor, New Haven, United States

MorganHoratio Jul. 2 at 11:21 PM

One of the strongest sectors outside of AI right now is Biotech. Rare Diseases $LQDA Liquidia $MBX MBX Biosciences $EWTX Edgewise Therapeutics $TVTX Travere Therapeutics $TRVI Trevi Therapeutics Money is rotating into the massive breakout trend: Rare Disease Biotech! The momentum here is wild: TVTX surged nearly 2.8x over the past year on key FDA milestones, while EWTX and TRVI both just clocked fresh all-time highs fueled by stellar data. Together with LQDA and MBX, rare disease plays offer high pricing power and exclusive markets, making them the ultimate safe haven with explosive high-beta potential. Can Rare Diseases outpace AI in H2? Which ticker is your top play: LQDA, MBX, EWTX, TVTX, or TRVI? Drop your picks below! 👇

4 · Reply

Drew613 Jun. 30 at 11:08 AM

$TRVI still waiting for the BO announcement. Let’s have it! Super

0 · Reply

abcdzepeda Jun. 26 at 12:46 AM

$TRVI can someone please explain to me how we trade over 3,583,000 shares and only close at $18 dollars!

0 · Reply

hmandude Jun. 24 at 10:11 PM

$TRVI 3.8m shares traded today and 2m shares traded AH….

1 · Reply

abcdzepeda Jun. 23 at 8:23 PM

$TRVI almost 3,000,000 shares traded today and we closed lower than what we opened at! Hmmm!

2 · Reply

hmandude Jun. 22 at 3:00 PM

$TRVI Over a million shares traded already? If this is a buyout soon, this has been telegraphed. Those options and the high volume lately give it away if it happens.

0 · Reply

Drew613 Jun. 22 at 12:23 AM

$TRVI IMO, BO getting close in the $30’s. Not an investment advice though!

0 · Reply

Strangperson Jun. 18 at 11:55 PM

$TRVI @doncorleone77

0 · Reply

dartgator Jun. 18 at 6:33 PM

$TRVI amazingly bullish! Can we close at $17 today?

1 · Reply

hmandude Jun. 18 at 4:18 PM

$TRVI High volume again. The call buyer rolled their June calls to July $15/16 strikes.

0 · Reply

Trevi Therapeutics Announces Upcoming June and July Event Schedule

Jun 3, 2026, 11:00 AM EDT - 4 weeks ago

Trevi Therapeutics Transcript: AGM 2026

May 12, 2026, 8:15 PM EDT - 7 weeks ago

Trevi Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-08T12:40:21.000Z - 2 months ago

Trevi Therapeutics price target raised to $30 from $18 at Stifel

2026-05-07T22:19:41.000Z - 2 months ago

Trevi Therapeutics price target raised to $29 from $21 at Clear Street

May 7, 2026, 10:00 AM EDT - 2 months ago

Trevi Therapeutics Transcript: Investor Day 2026

May 7, 2026, 10:00 AM EDT - 2 months ago

Trevi Therapeutics Slides: FY 2026

2026-05-07T08:18:06.000Z - 2 months ago

Trevi Therapeutics price target raised to $20 from $18 at Morgan Stanley

May 5, 2026, 4:30 PM EDT - 2 months ago

Trevi Therapeutics Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

Trevi Therapeutics Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

Trevi Therapeutics Quarterly report: Q1 2026

May 5, 2026, 4:05 PM EDT - 2 months ago

Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Apr 30, 2026, 4:05 PM EDT - 2 months ago

Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference

ATS

Apr 28, 2026, 4:05 PM EDT - 2 months ago

Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026

Apr 23, 2026, 4:05 PM EDT - 2 months ago

Trevi Therapeutics to Participate in Upcoming May Events

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Trevi Therapeutics Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Trevi Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 4:05 PM EDT - 2 months ago

Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

2026-04-17T10:32:43.000Z - 2 months ago

Trevi Therapeutics 11.6M share Spot Secondary priced at $13.00

Apr 16, 2026, 10:42 PM EDT - 2 months ago

Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

2026-04-16T20:12:56.000Z - 2 months ago

Trevi Therapeutics announces $150M common stock offering

Apr 16, 2026, 4:08 PM EDT - 2 months ago

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Trevi Therapeutics Proxy statement: Proxy filing

Apr 1, 2026, 7:30 AM EDT - 3 months ago

Trevi Therapeutics to Participate in Upcoming Events

2026-03-19T12:45:37.000Z - 3 months ago

Trevi Therapeutics price target lowered to $24 from $25 at JonesResearch

2026-03-18T12:19:40.000Z - 3 months ago

Trevi Therapeutics price target lowered to $18 from $19 at Morgan Stanley

Mar 17, 2026, 4:30 PM EDT - 3 months ago

Trevi Therapeutics Earnings Call Transcript: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 3 months ago

Trevi Therapeutics Annual report: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 3 months ago

Trevi Therapeutics Earnings release: Q4 2025

2026-03-17T20:25:44.000Z - 3 months ago

Trevi Therapeutics reports Q4 EPS (6c), consensus (10c)

Mar 17, 2026, 4:05 PM EDT - 3 months ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

Mar 11, 2026, 8:40 AM EDT - 4 months ago

Trevi Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 4:05 PM EDT - 4 months ago

Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

2026-03-09T17:20:09.000Z - 4 months ago

Trevi completes EOP2 with FDA, on track for Q2 Phase 3 initiation, says Stifel

2026-03-09T11:41:08.000Z - 4 months ago

Trevi Therapeutics completes End-of-Phase 2 meeting with FDA

Mar 9, 2026, 7:30 AM EDT - 4 months ago

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough

Mar 2, 2026, 7:30 AM EST - 4 months ago

Trevi Therapeutics to Participate in Upcoming March Conferences

Feb 17, 2026, 7:30 AM EST - 4 months ago

Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-22T17:35:14.000Z - 5 months ago

Trevi announces publication of data from Phase 2b IPF chronic cough trial

Jan 22, 2026, 12:30 PM EST - 5 months ago

Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)

Jan 8, 2026, 7:30 AM EST - 6 months ago

Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

2025-12-19T12:55:58.000Z - 7 months ago

Trevi Therapeutics price target raised to $18 from $15 at Stifel

2025-12-04T12:36:30.000Z - 7 months ago

Trevi Therapeutics appoints David Hastings as CFO

Dec 4, 2025, 7:30 AM EST - 7 months ago

Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

2025-11-20T14:35:14.000Z - 8 months ago

Trevi Therapeutics price target raised to $16 from $13 at Leerink

2025-11-14T13:20:21.000Z - 8 months ago

Trevi Therapeutics price target raised to $19 from $18 at Morgan Stanley

2025-11-14T12:45:24.000Z - 8 months ago

Trevi Therapeutics price target raised to $24 from $23 at Oppenheimer

2025-11-14T11:00:55.000Z - 8 months ago

Trevi Therapeutics price target raised to $21 from $11 at Clear Street

Nov 13, 2025, 4:30 PM EST - 8 months ago

Trevi Therapeutics Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Trevi Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Trevi Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 4:05 PM EST - 8 months ago

Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 6, 2025, 4:05 PM EST - 8 months ago

Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

Nov 4, 2025, 7:30 AM EST - 8 months ago

Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

Oct 8, 2025, 7:30 AM EDT - 9 months ago

Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting

Sep 18, 2025, 7:30 AM EDT - 10 months ago

Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

Sep 9, 2025, 4:05 PM EDT - 10 months ago

Trevi Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 2:10 PM EDT - 10 months ago

Trevi Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 7:30 AM EDT - 11 months ago

Trevi Therapeutics to Participate in Upcoming September Conferences

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Trevi Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Trevi Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Trevi Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 11 months ago

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 4:05 PM EDT - 1 year ago

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

Jul 29, 2025, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming August Conferences

Jul 1, 2025, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

Jun 5, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jun 3, 2025, 10:15 PM EDT - 1 year ago

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

Jun 2, 2025, 8:30 AM EDT - 1 year ago

Trevi Therapeutics Transcript: Study Result

Jun 2, 2025, 8:30 AM EDT - 1 year ago

Trevi Therapeutics Press release: Study Result

Jun 2, 2025, 8:30 AM EDT - 1 year ago

Trevi Therapeutics Slides: Study Result

Jun 2, 2025, 7:00 AM EDT - 1 year ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Jun 1, 2025, 4:00 PM EDT - 1 year ago

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

May 29, 2025, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming June Conferences

$Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

May 20, 2025, 7:00 AM EDT - 1 year ago

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

May 8, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 1, 2025, 4:05 PM EDT - 1 year ago

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Trevi Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Trevi Therapeutics Proxy statement: Proxy Filing

Apr 7, 2025, 11:00 AM EDT - 1 year ago

Trevi Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Earnings Call Transcript: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Annual report: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Trevi Therapeutics Earnings release: Q4 2024

Mar 18, 2025, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Mar 11, 2025, 4:05 PM EDT - 1 year ago

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Trevi Therapeutics Transcript: Study Result

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Trevi Therapeutics Press release: Study Result

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Trevi Therapeutics Slides: Study Result

$Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

Mar 10, 2025, 6:00 AM EDT - 1 year ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

$Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

Mar 9, 2025, 4:00 PM EDT - 1 year ago

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Feb 27, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Feb 25, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Feb 11, 2025, 9:20 AM EST - 1 year ago

Trevi Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Jan 30, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

Jan 8, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Dec 16, 2024, 7:36 AM EST - 1 year ago

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Dec 12, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Dec 3, 2024, 5:00 PM EST - 1 year ago

Trevi Therapeutics Transcript: Study Update

Dec 3, 2024, 5:00 PM EST - 1 year ago

Trevi Therapeutics Press release: Study Update

Dec 3, 2024, 4:05 PM EST - 1 year ago

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Nov 21, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 18, 2024, 11:30 AM EST - 1 year ago

Trevi Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 6, 2024, 4:30 PM EST - 1 year ago

Trevi Therapeutics Earnings Call Transcript: Q3 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

Trevi Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

Trevi Therapeutics Earnings release: Q3 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

MorganHoratio Jul. 2 at 11:21 PM

4 · Reply

Drew613 Jun. 30 at 11:08 AM

$TRVI still waiting for the BO announcement. Let’s have it! Super

0 · Reply

abcdzepeda Jun. 26 at 12:46 AM

$TRVI can someone please explain to me how we trade over 3,583,000 shares and only close at $18 dollars!

0 · Reply

hmandude Jun. 24 at 10:11 PM

$TRVI 3.8m shares traded today and 2m shares traded AH….

1 · Reply

abcdzepeda Jun. 23 at 8:23 PM

$TRVI almost 3,000,000 shares traded today and we closed lower than what we opened at! Hmmm!

2 · Reply

hmandude Jun. 22 at 3:00 PM

$TRVI Over a million shares traded already? If this is a buyout soon, this has been telegraphed. Those options and the high volume lately give it away if it happens.

0 · Reply

Drew613 Jun. 22 at 12:23 AM

$TRVI IMO, BO getting close in the $30’s. Not an investment advice though!

0 · Reply

Strangperson Jun. 18 at 11:55 PM

$TRVI @doncorleone77

0 · Reply

dartgator Jun. 18 at 6:33 PM

$TRVI amazingly bullish! Can we close at $17 today?

1 · Reply

hmandude Jun. 18 at 4:18 PM

$TRVI High volume again. The call buyer rolled their June calls to July $15/16 strikes.

0 · Reply

Doozio Jun. 17 at 9:08 PM

$TRVI east side crew ONTO 🐒🍌🧠⏰♾️

1 · Reply

dartgator Jun. 17 at 1:52 PM

$TRVI wow steadily moving up !

1 · Reply

abcdzepeda Jun. 17 at 2:19 AM

$TRVI Waz up!!!

0 · Reply

dartgator Jun. 16 at 8:17 PM

$TRVI what’s going on here? The chart looks very bullish!

2 · Reply

Strangperson Jun. 16 at 7:50 PM

$TRVI

0 · Reply

Bfunk17 Jun. 16 at 6:50 PM

$TRVI Looking good.

0 · Reply

hmandude Jun. 16 at 6:38 PM

$TRVI It’s getting a bit interesting again. Higher volume. All those options expire on Friday that someone bought a while back. We’ll see…

0 · Reply

BioTechHealthX Jun. 14 at 4:06 PM

$TRVI Trevi Therapeutics Inc. (NASDAQ: TRVI) is gaining attention among small-cap biotech stocks thanks to Haduvio, its focused pipeline, and a cash runway expected to stretch into 2030. Is this under-the-radar biotech stock quietly building a stronger case for investors? https://biotechhealthx.com/biotech-news/is-trevi-therapeutics-trvi-the-hidden-biotech-stock-investors-are-missing/

0 · Reply

BioTechHealthX Jun. 12 at 9:49 AM

$ARQT $AUPH $CPRX $OCUL $TRVI From cancer cell therapy to rare disease treatments and eye-disease breakthroughs, these small-cap biotech stocks are chasing major medical markets. Here are 10 biotech companies drawing attention for their pipelines, revenue growth, and upside potential. https://biotechhealthx.com/biotech-news/top-5-small-cap-biotech-stocks-that-could-surge-100/

0 · Reply

Bfunk17 Jun. 8 at 8:05 PM

$TRVI My favorite mid-late summer BO. BCRX and TGTX are dragging to that BO finishline. I like them both for 2026. TRVI's time I feel is coming soon. We shall see.

1 · Reply

SuperGreenToday Jun. 5 at 2:43 PM

$TRVI Share Price: $13.85 Contract Selected: Jan 15, 2027 $15 Calls Buy Zone: $0.26 – $0.32 Target Zone: $0.47 – $0.57 Potential Upside: 74% ROI Time to Expiration: 223 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BioTechHealthX May. 23 at 8:14 AM

$TRVI Trevi Therapeutics is developing Haduvio for difficult chronic cough conditions that affect quality of life. With positive Phase 2 results, TRVI is building a biotech story investors may not want to ignore. https://biotechhealthx.com/biotech-news/is-trevi-therapeutics-trvi-a-good-biotech-stock-to-buy-before-its-next-haduvio-catalyst/

0 · Reply

Market Cap	2.55B
Revenue (ttm)	0.00
Net Income (ttm)	-42.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,206,500
Avg Vol	1,783,416
Day's Range	N/A - N/A
Shares Out	141.98M
Stochastic %K	37%
Beta	1.00
Analysts	Strong Sell
Price Target	$23.92